Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days Source: Eur Respir J 2002; 20: Suppl. 38, 197s Year: 2002
Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma Source: Eur Respir J 2004; 23: 354-355 Year: 2004
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006
Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011
Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Effect of add-on montelukast to inhaled corticosteroids on excessive airway narrowing in adult asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Dissociation in effects of fluticasone but not fluticasone/salmeterol on lung function and airway hyperresponsiveness in mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002
Reduction of respiratory resistance after fluticasone inhaled therapy in asthmatic preschool children Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004
Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma Source: Eur Respir J 2003; 21: 633-636 Year: 2003
High doses of inhaled fluticasone propionate dose-dependently suppress adrenal cortical function in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006